IDP-121
Phase 2Small molecule
IDP-121 is one of 45 small molecule programs targeting Small Cell Lung Cancer ( SCLC ). It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Hematologic Malignancies
#DrugCompanyPhaseTrials
1Avycaz
PPhiladelphia Eye Associates
Approved
Cellcept
RochePhase 2
Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Cytosar
TevaPhase 2
Atgam
NovartisPhase 2
Trexall
Jazz PharmaceuticalsPhase 2
Prograf
VVeloxis Pharmaceuticals
Phase 2
Adriamycin
PfizerPhase 2
Jakafi
IncytePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IDP-121. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIDP Discovery Pharma S.L.